Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
Kang Wang, Yunlong Cao, Yunjiao Zhou, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
Zhen Cui, Pan Liu, Nan Wang, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 860-871.e13
Open Access | Times Cited: 387
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Frauke Muecksch, Zijun Wang, Alice Cho, et al.
Nature (2022) Vol. 607, Iss. 7917, pp. 128-134
Open Access | Times Cited: 273
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Gang Zeng, Qianhui Wu, Hongxing Pan, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 4, pp. 483-495
Open Access | Times Cited: 269
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Kang Wang, Zijing Jia, Linilin Bao, et al.
Nature (2022) Vol. 603, Iss. 7903, pp. 919-925
Open Access | Times Cited: 171
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
Fanglei Zuo, Hassan Abolhassani, Likun Du, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 142
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Yihao Liu, Qin Zeng, Caiguanxi Deng, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 122
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
Felipe Melo-González, Jorge A. Soto, Liliana A González, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 76
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Zhenhao Fang, Lei Peng, Renata B. Filler, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 51
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
Bárbara M. Schultz, Felipe Melo-González, Luisa F. Duarte, et al.
mBio (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 42
Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study
Jingwen Ai, Yi Zhang, Haocheng Zhang, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 639-647
Open Access | Times Cited: 41
Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
Yubin Liu, Ziyi Wang, Xinyu Zhuang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 33
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
Ritthideach Yorsaeng, Nungruthai Suntronwong, Harit Phowatthanasathian, et al.
Vaccine (2021) Vol. 40, Iss. 3, pp. 524-530
Open Access | Times Cited: 55
Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS‐CoV‐2: A longitudinal study
Zeynep Ece Kuloğlu, Rojbin El, Gülen Güney-Esken, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2459-2467
Open Access | Times Cited: 23
The mechanisms of immune response and evasion by the main SARS-CoV-2 variants
Qiuli Chen, Jiawei Zhang, Peter Wang, et al.
iScience (2022) Vol. 25, Iss. 10, pp. 105044-105044
Open Access | Times Cited: 22
Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant
Fanglei Zuo, Hassan Abolhassani, Likun Du, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 21
Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through multiple mechanisms
Pan Liu, Can Yue, Bo Meng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques
Wei Deng, Qi Lv, Fengdi Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 18
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Xiaoman Li, Yongbing Pan, Qiangling Yin, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 18
Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
Bin Ju, Bing Zhou, Shuo Song, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 2
Open Access | Times Cited: 17
Distinct Conformations of SARS-CoV-2 Omicron Spike Protein and Its Interaction with ACE2 and Antibody
Myeongsang Lee, Marian Major, Huixiao Hong
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3774-3774
Open Access | Times Cited: 10
A highly immunogenic live-attenuated vaccine candidate prevents SARS-CoV-2 infection and transmission in hamsters
Xiaofeng Li, Zhen Cui, Hang Fan, et al.
The Innovation (2022) Vol. 3, Iss. 2, pp. 100221-100221
Open Access | Times Cited: 15
Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
Jianyang Liu, Qunying Mao, Xing Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China
Guang Zeng, Liumei Xu, Shuidong Feng, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 880-880
Open Access | Times Cited: 14
Structural and functional characterizations of altered infectivity and immune evasion of SARS-CoV-2 Omicron variant
Zhen Cui, Pan Liu, Nan Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 16
“Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety” [Response To Letter]
Maria Teresa Mascellino, Federica Di Timoteo, Massimiliano De Angelis, et al.
Infection and Drug Resistance (2021) Vol. Volume 14, pp. 4501-4502
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top